Yuqi Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuqi Yan has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Dong Xu
Department of Diagnostic Ultrasound Imaging & Interventional Therapy, Hangzhou Institute of Medicine (HIM), Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou, China
4 shared publications - Liping Wang
Department of Diagnostic Ultrasound Imaging & Interventional Therapy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
3 shared publications - Chen Chen
Department of Diagnostic Ultrasound Imaging & Interventional Therapy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
2 shared publications - Jian Liu
School of Information and Control Engineering, China University of Mining and Technology, Xuzhou, China
2 shared publications - Qian Song
Department of Gynecology and Obstetrics, Taizhou Cancer Hospital, Taizhou, China
2 shared publications - Xinzheng Xue
School of Information and Control Engineering, China University of Mining and Technology, Xuzhou, China
2 shared publications
Latest Publications
- 24 April 2026
- Published by Springer Nature in International Journal of Machine Learning and Cybernetics
- Vol. 17 (6) , 260
Breast cancer HER2 status recognition based on dual-modal feature attention fusion network
- 24 April 2026
- Published by Springer Nature in International Journal of Machine Learning and Cybernetics
- Vol. 17 (6) , 260
Breast cancer HER2 status recognition based on dual-modal feature attention fusion network
- 7 March 2026
- Published by Elsevier in Academic Radiology
- Vol. 33 (6) , 2507-2520
Ultrasound Video-Based Deep Learning Model for Predicting Axillary Lymph Node Status and Nodal Burden in Breast Cancer
- 7 March 2026
- Published by Elsevier in Academic Radiology
- Vol. 33 (6) , 2507-2520
Ultrasound Video-Based Deep Learning Model for Predicting Axillary Lymph Node Status and Nodal Burden in Breast Cancer
- 5 August 2025
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 271, 108987
Prediction of breast cancer HER2 status changes based on ultrasound radiomics attention network
- 5 August 2025
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 271, 108987
Prediction of breast cancer HER2 status changes based on ultrasound radiomics attention network
- Open Access
- 28 August 2023
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 202 (1) , 45-55
Ultrasound and clinicopathological characteristics-based model for prediction of pathologic response to neoadjuvant chemotherapy in HER2-positive breast cancer: a case–control study
Background: The objective of this study was to develop a model combining ultrasound (US) and clinicopathological characteristics to predict the pathologic response to neoadjuvant chemotherapy (NACT) in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Materials and methods: This is a retrospective study that included 248 patients with HER2-positive breast cancer who underwent NACT from March 2018 to March 2022. US and clinicopathological characteristics were collected from all patients in this study, and characteristics obtained using univariate analysis at p < 0.1 were subjected to multivariate analysis and then the conventional US and clinicopathological characteristics independently associated with pathologic complete response (pCR) from the analysis were used to develop US models, clinicopathological models, and their combined models by the area under the receiver operating characteristic (ROC) curve (AUC), accuracy, sensitivity, and specificity to assess their predictive efficacy. Results: The combined model had an AUC of 0.808, a sensitivity of 88.72%, a specificity of 60.87%, and an accuracy of 75.81% in predicting pCR of HER2-positive breast cancer after NACT, which was significantly better than the clinicopathological model (AUC = 0.656) and the US model (AUC = 0.769). In addition, six characteristics were screened as independent predictors, namely the Clinical T stage, Clinical N stage, PR status, posterior acoustic, margin, and calcification. Conclusion: The conventional US combined with clinicopathological characteristics to construct a combined model has a good diagnostic effect in predicting pCR in HER2-positive breast cancer and is expected to be a useful tool to assist clinicians in effectively determining the efficacy of NACT in HER2-positive breast cancer patients.
- 28 August 2023
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 202 (1) , 45-55
Open AccessUltrasound and clinicopathological characteristics-based model for prediction of pathologic response to neoadjuvant chemotherapy in HER2-positive breast cancer: a case–control study
Background: The objective of this study was to develop a model combining ultrasound (US) and clinicopathological characteristics to predict the pathologic response to neoadjuvant chemotherapy (NACT) in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Materials and methods: This is a retrospective study that included 248 patients with HER2-positive breast cancer who underwent NACT from March 2018 to March 2022. US and clinicopathological characteristics were collected from all patients in this study, and characteristics obtained using univariate analysis at p < 0.1 were subjected to multivariate analysis and then the conventional US and clinicopathological characteristics independently associated with pathologic complete response (pCR) from the analysis were used to develop US models, clinicopathological models, and their combined models by the area under the receiver operating characteristic (ROC) curve (AUC), accuracy, sensitivity, and specificity to assess their predictive efficacy. Results: The combined model had an AUC of 0.808, a sensitivity of 88.72%, a specificity of 60.87%, and an accuracy of 75.81% in predicting pCR of HER2-positive breast cancer after NACT, which was significantly better than the clinicopathological model (AUC = 0.656) and the US model (AUC = 0.769). In addition, six characteristics were screened as independent predictors, namely the Clinical T stage, Clinical N stage, PR status, posterior acoustic, margin, and calcification. Conclusion: The conventional US combined with clinicopathological characteristics to construct a combined model has a good diagnostic effect in predicting pCR in HER2-positive breast cancer and is expected to be a useful tool to assist clinicians in effectively determining the efficacy of NACT in HER2-positive breast cancer patients.